Author

N. T. Ueno

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

B. G. Debeb· 3 shared D. Tripathy· 3 shared E. Schlee Villodre· 3 shared J. Song· 3 shared S. Krishnamurthy· 3 shared W. A. Woodward· 3 shared R. A. Larson· 2 shared X. Hu· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. G. Debeb

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer

K. Balamurugan, S. Sehareen, S. Sharan, S. Krishnamurthy, W. Tang, L. McKennett, V. Padmanaba, K. T. Czarra, A. J. Ewald, S. Ambs, N. T. Ueno, D. K. Poria, E. Sterneck

This study identifies COX-2/GSK3β signaling as a mechanism maintaining E-cadherin adhesions in metastatic breast cancer, showing that targeting this pathway reduces metastasis and improves outcomes.

bioRxiv · Jan 18, 2022Cancer Biology

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

C. M. Yamazaki, A. Yamaguchi, Y. Anami, W. Xiong, Y. Otani, J. Lee, N. T. Ueno, N. Zhang, Z. An, K. Tsuchikama

This study develops dual-payload antibody-drug conjugates to overcome breast tumor heterogeneity and drug resistance, showing improved efficacy in a xenograft model.

Nature Communications · Jun 10, 2021Peer-reviewedBioengineering

Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion

E. Schlee Villodre, X. Hu, R. A. Larson, P. Finetti, K. Gomez, W. Balema, S. R. Stecklein, G. Santiago-Sanchez, S. Krishnamurthy, J. Song, X. Su, N. T. Ueno, D. Tripathy, S. Van Laere, F. Bertucci, , B. G. Debeb

This study shows that lipocalin 2 promotes inflammatory breast cancer aggressiveness and skin invasion by enhancing proliferation, migration, and metastasis.

bioRxiv · Mar 18, 2021Cancer Biology

NDRG1 expression is an independent prognostic factor in inflammatory breast cancer

E. Schlee Villodre, Y. Gong, L. Huo, E. C. Yoon, N. T. Ueno, W. A. Woodward, D. Tripathy, J. Song, B. G. Debeb

This study shows NDRG1 expression is an independent predictor of poor survival in inflammatory breast cancer patients.

bioRxiv · Sep 25, 2020Cancer Biology

Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer

X. Hu, E. Schlee Villodre, R. A. Larson, O. M. Rahal, X. Wang, Y. Gong, J. Song, S. Krishnamurthy, N. T. Ueno, D. Tripathy, W. A. Woodward, B. G. Debeb

This study identifies decorin as a negative regulator of E-cadherin in inflammatory breast cancer, showing it reduces migration, invasion, and metastasis by destabilizing E-cadherin and inhibiting EGFR/ERK signaling.

bioRxiv · Jul 7, 2020Cancer Biology